polyethylene glycol 3350 nf- polyethylene glycol 3350 powder, for solution
nuvo pharmaceutical inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - osmotic laxative - relieves occasional constipation (irregularity) - generally produces a bowel movement in 1 to 3 days taking a prescription drug - you have rectal bleeding or your nausea, bloating, cramping or abdominal pain gets worse. these may be signs of a serious condition. - you get diarrhea - you need to use a laxative for longer than 1 week
polyethylene glycol 3350 nf- polyethylene glycol 3350 powder, for solution
sunrise pharmaceutical, inc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - osmotic laxative - relieves occasional constipation (irregularity) - generally produces a bowel movement in 1 to 3 days taking a prescription drug - you have rectal bleeding or your nausea, bloating, cramping or abdominal pain gets worse. these may be signs of a serious condition. - you get diarrhea - you need to use a laxative for longer than 1 week
polyethylene glycol 3350 powder, for solution
strides pharma inc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - osmotic laxative osmotic laxative - relieves occasional constipation (irregularity) - generally produces a bowel movement in 1 to 3 days
polyethylene glycol 3350 powder, for solution
lannett company, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - polyethylene glycol 3350 17 g in 17 g - laxative - relieves occasional constipation (irregularity) - generally produces a bowel movement in 1 to 3 days
peg-3350, sodium chloride, sodium bicarbonate and potassium chloride- polyethylene glycol 3350, sodium chloride, sodium bicarbon
affordable pharmaceuticals, llc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - polyethylene glycol 3350 420 g in 4 l - peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution [see how supplied/storage and handling ( 16)] animal reproduction studies have not been conducted with peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution. it is also not known whether peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution can cause fetal harm when administered to a pregnant woman or can affect reproductive
moviprep- polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate kit
salix pharmaceuticals, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 100 g in 1 l - moviprep® is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. moviprep is contraindicated in the following conditions: risk summary there are no available data on moviprep in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with moviprep. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available on the presence of moviprep in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determination of the risk o
gavilyte-n- polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate powder, for solution
lupin pharmaceuticals,inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 420 g in 438.4 g - gavilyte-n is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. gavilyte-n is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of gavilyte-n for oral solution [see how supplied/storage and handling (16)] animal reproduction studies have not been conducted with gavilyte-n. it is also not known whether gavilyte-n can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. gavilyte-n should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when gavilyte-n is administered to a nursing woman. safety and effectiveness of gavilyte-n in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of gavilyte-n in adults with additional safety and efficacy data from published studies of similar formulations. use of gavilyte-n in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. dehydration has been reported in one child and hypokalemia has been reported in 3 children. clinical studies of gavilyte-n did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.
nulytely with flavor packs- polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride kit
braintree laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - polyethylene glycol 3350 420 g in 4 l - nulytely is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. nulytely is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of nulytely [ see how supplied/storage and handling ( 16) ] pregnancy category c. animal reproduction studies have not been conducted with nulytely. it is also not known whether nulytely can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. nulytely should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when nulytely is administered to a nursing woman. safety and effectiveness of nulyte
trilyte with flavor packs- polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for sol
wallace pharmaceuticals inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 420 g in 4 l - trilyte is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. trilyte is contraindicated in the following conditions: animal reproduction studies have not been conducted with trilyte. it is also not known whether trilyte can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. trilyte should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when trilyte is administered to a nursing woman. safety and effectiveness of trilyte in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of trilyte in adults with additional safety and efficacy data from published studies of similar formulations. use of trilyte in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as
polyethylene glycol 3350 powder, for solution
nexgen pharma, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p) - for the treatment of occasional constipation. this product should be used for 2 weeks or less or as directed by a physician. polyethylene glycol 3350 nf is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol. there have been no reports of accidental overdosage. in the event of overdosage, diarrhea would be the expected major event. if an overdose of drug occurred without concomitant ingestion of fluid, dehydration due to diarrhea may result. medication should be terminated and free water administered. the oral ld50 is > 50 gm/kg in mice, rats and rabbits.